Abstract:The study of modified RNA known as epitranscriptomics has become increasingly relevant in our understanding of disease-modifying mechanisms. Methylation of N6 adenosine (m6A) and C5 cytosine (m5C) bases occur on mRNAs, tRNA, mt-tRNA, and rRNA species as well as non-coding RNAs. With emerging knowledge of RNA binding proteins that act as writer, reader, and eraser effector proteins, comes a new understanding of physiological processes controlled by these systems. Such processes when spatiotemporally disrupted within cellular nanodomains in highly specialized tissues such as the brain, give rise to different forms of disease. In this review, we discuss accumulating evidence that changes in the m6A and m5C methylation systems contribute to neurocognitive disorders. Early studies first identified mutations within FMR1 to cause intellectual disability Fragile X syndromes several years before FMR1 was identified as an m6A RNA reader protein. Subsequently, familial mutations within the m6A writer gene METTL5, m5C writer genes NSUN2, NSUN3, NSUN5, and NSUN6, as well as THOC2 and THOC6 that form a protein complex with the m5C reader protein ALYREF, were recognized to cause intellectual development disorders. Similarly, differences in expression of the m5C writer and reader effector proteins, NSUN6, NSUN7, and ALYREF in brain tissue are indicated in individuals with Alzheimer's disease, individuals with a high neuropathological load or have suffered traumatic brain injury. Likewise, an abundance of m6A reader and anti-reader proteins are reported to change across brain regions in Lewy bodies diseases, Alzheimer's disease, and individuals with high cognitive reserve. m6A-modified RNAs are also reported significantly more abundant in dementia with Lewy bodies brain tissue but significantly reduced in Parkinson's disease tissue, whilst modified RNAs are misplaced within diseased cells, particularly where synapses are located. In parahippocampal brain tissue, m6A modification is enriched in transcripts associated with psychiatric disorders including conditions with clear cognitive deficits. These findings indicate a diverse set of molecular mechanisms are influenced by RNA methylation systems that can cause neuronal and synaptic dysfunction underlying neurocognitive disorders. Targeting these RNA modification systems brings new prospects for neural regenerative therapies.

Unraveling the Pathways to Neuronal Homeostasis and Disease: Mechanistic Insights into the Role of RNA-Binding Proteins and Associated Factors

RNA-binding proteins in neurological development and disease

Non-Coding RNAs in Neurological and Neuropsychiatric Disorders: Unraveling the Hidden Players in Disease Pathogenesis

Post-translational Control of RNA-Binding Proteins and Disease-Related Dysregulation

Altered mRNA transport and local translation in iNeurons with RNA binding protein knockdown

RNA modulates physiological and neuropathological protein phase transitions

Dysregulation of RNA modification systems in clinical populations with neurocognitive disorders

Role of non-coding RNAs in non-aging-related neurological disorders

Post-Transcriptional Trafficking and Regulation of Neuronal Gene Expression

TDP-43 and NEAT long non-coding RNA: Roles in neurodegenerative disease

RNA–protein interactions and control of mRNA stability in neurons

The effect of RNA binding proteins on neurodevelopment and neurological disease

Stress granules and neurodegeneration

Nonsense-mediated RNA decay in the brain: emerging modulator of neural development and disease

tRNA Modifications and Dysregulation: Implications for Brain Diseases

Counter-regulation of RNA stability by UPF1 and TDP43

Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson's disease and synucleinopathies

Axon guidance genes are regulated by TDP-43 and RGNEF through long-intron removal

Regulation of DNA damage response by RNA/DNA-binding proteins: Implications for neurological disorders and aging

RNA-binding proteins in human genetic disease

U1 Snrnp Biogenesis Deffects In Neurodegenerative Diseases